ZA97327B - Substituted histidine inhibitors of protein farnesyltransferase - Google Patents

Substituted histidine inhibitors of protein farnesyltransferase

Info

Publication number
ZA97327B
ZA97327B ZA97327A ZA97327A ZA97327B ZA 97327 B ZA97327 B ZA 97327B ZA 97327 A ZA97327 A ZA 97327A ZA 97327 A ZA97327 A ZA 97327A ZA 97327 B ZA97327 B ZA 97327B
Authority
ZA
South Africa
Prior art keywords
inhibitors
protein farnesyltransferase
substituted histidine
histidine
substituted
Prior art date
Application number
ZA97327A
Other languages
English (en)
Inventor
Annette Marian Doherty
James Stanley Kaltenbronn
Daniele Leonard
John Quin Iii
Jeffrey David Scholten
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of ZA97327B publication Critical patent/ZA97327B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
ZA97327A 1996-01-16 1997-01-15 Substituted histidine inhibitors of protein farnesyltransferase ZA97327B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US995696P 1996-01-16 1996-01-16

Publications (1)

Publication Number Publication Date
ZA97327B true ZA97327B (en) 1997-07-22

Family

ID=21740700

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA97327A ZA97327B (en) 1996-01-16 1997-01-15 Substituted histidine inhibitors of protein farnesyltransferase

Country Status (4)

Country Link
US (1) US6008372A (fr)
AU (1) AU1529997A (fr)
WO (1) WO1997026246A1 (fr)
ZA (1) ZA97327B (fr)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6146842A (en) * 1998-09-21 2000-11-14 Mitotix, Inc. High-throughput screening assays utilizing metal-chelate capture
CA2360740A1 (fr) 1999-03-02 2000-09-08 Boehringer Ingelheim Pharmaceuticals, Inc. Composes utiles en tant qu'inhibiteurs reversibles de la cathepsine s
US6420364B1 (en) 1999-09-13 2002-07-16 Boehringer Ingelheim Pharmaceuticals, Inc. Compound useful as reversible inhibitors of cysteine proteases
FR2839974B1 (fr) * 2002-05-24 2004-07-16 Pf Medicament Derives de phenyl-furane ou de phenyl-thiophene,leur preparation et leur application a titre de medicament
JP4866233B2 (ja) * 2003-04-29 2012-02-01 ウニヴェルジテート・チューリッヒ ｆａｃ配位により高効率で［Ｍ（ＯＨ２）３（ＣＯ）３］＋標識化するために生体分子にカップリングさせるための、Ｎεおよび／またはＮαで誘導体化され、金属および有機保護されたＬ−ヒスチジン
ES2382814T3 (es) 2005-05-17 2012-06-13 Merck Sharp & Dohme Ltd. Ácido cis-4-[(4-clorofenil)sulfonil]-4-(2,5-difluorofenil)ciclohexanopropanoico para el tratamiento del cáncer
GB0603041D0 (en) 2006-02-15 2006-03-29 Angeletti P Ist Richerche Bio Therapeutic compounds
CA2664113C (fr) 2006-09-22 2013-05-28 Merck & Co., Inc. Utilisation de la platencine et de la platensimycine en tant qu'inhibiteurs de la synthese des acides gras pour traiter l'obesite, lediabete et le cancer
US20110218176A1 (en) 2006-11-01 2011-09-08 Barbara Brooke Jennings-Spring Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development
BRPI0806245B1 (pt) 2007-01-10 2022-01-25 Msd Italia S.R.L. Compostos de fórmula i e seus usos
BRPI0808523A2 (pt) 2007-03-01 2014-08-19 Novartis Vaccines & Diagnostic Inibidores de pim cinase e métodos de seu uso
CA2685967A1 (fr) 2007-05-21 2008-11-21 Novartis Ag Inhibiteurs de cfs-1r, compositions et methodes d'utilisation connexes
EP2170076B1 (fr) 2007-06-27 2016-05-18 Merck Sharp & Dohme Corp. Dérivés de 4-carboxybenzylamino utilisés en tant qu'inhibiteurs de l'histone désacétylase
US8691825B2 (en) 2009-04-01 2014-04-08 Merck Sharp & Dohme Corp. Inhibitors of AKT activity
WO2010144909A1 (fr) 2009-06-12 2010-12-16 Novartis Ag Composés hétérocycliques fondus et leurs utilisations
WO2011046771A1 (fr) 2009-10-14 2011-04-21 Schering Corporation Pipéridines substituées qui accroissent l'activité de p53, et utilisations de ces composés
CA2784807C (fr) 2009-12-29 2021-12-14 Dana-Farber Cancer Institute, Inc. Inhibiteurs de kinase raf de type ii
CN103080093A (zh) 2010-03-16 2013-05-01 达纳－法伯癌症研究所公司 吲唑化合物及其应用
WO2011163330A1 (fr) 2010-06-24 2011-12-29 Merck Sharp & Dohme Corp. Nouveaux composés hétérocycliques utilisés comme inhibiteurs de erk
CA2805265A1 (fr) 2010-08-02 2012-02-09 Merck Sharp & Dohme Corp. Inhibition a mediation par interference arn de catenine (proteine associee a cadherine), expression du gene beta 1 (ctnnb1) a l'aide de petit acide nucleique interferent (sian)
WO2012024170A2 (fr) 2010-08-17 2012-02-23 Merck Sharp & Dohme Corp. Inhibition médiée par des arn interférents de l'expression génique du virus de l'hépatite b (vhb) à l'aide de petits acides nucléiques interférents (pani)
US8883801B2 (en) 2010-08-23 2014-11-11 Merck Sharp & Dohme Corp. Substituted pyrazolo[1,5-a]pyrimidines as mTOR inhibitors
US8946216B2 (en) 2010-09-01 2015-02-03 Merck Sharp & Dohme Corp. Indazole derivatives useful as ERK inhibitors
EP2615916B1 (fr) 2010-09-16 2017-01-04 Merck Sharp & Dohme Corp. Dérivés condensés de pyrazole utilisés comme nouveaux inhibiteurs erk
WO2012058210A1 (fr) 2010-10-29 2012-05-03 Merck Sharp & Dohme Corp. INHIBITION FACILITÉE PAR L'INTERFÉRENCE D'ARN DE L'EXPRESSION D'UN GÈNE AU MOYEN D'ACIDES NUCLÉIQUES INTERFÉRENTS COURTS (siNA)
WO2012087772A1 (fr) 2010-12-21 2012-06-28 Schering Corporation Dérivés d'indazole utiles en tant qu'inhibiteurs de erk
JP2014514321A (ja) 2011-04-21 2014-06-19 メルク・シャープ・アンド・ドーム・コーポレーション インスリン様増殖因子１受容体阻害剤
US9023865B2 (en) 2011-10-27 2015-05-05 Merck Sharp & Dohme Corp. Compounds that are ERK inhibitors
WO2013074986A1 (fr) 2011-11-17 2013-05-23 Dana-Farber Cancer Institute, Inc. Inhibiteurs de la kinase c-jun-n-terminale (jnk)
US20150299696A1 (en) 2012-05-02 2015-10-22 Sirna Therapeutics, Inc. SHORT INTERFERING NUCLEIC ACID (siNA) COMPOSITIONS
WO2014052563A2 (fr) 2012-09-28 2014-04-03 Merck Sharp & Dohme Corp. Nouveaux composés inhibiteurs de erk
US10112927B2 (en) 2012-10-18 2018-10-30 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 (CDK7)
WO2014063054A1 (fr) 2012-10-19 2014-04-24 Dana-Farber Cancer Institute, Inc. Inhibiteurs de kinase moelle osseuse sur chromosome x (bmx) et leurs utilisations
WO2014063061A1 (fr) 2012-10-19 2014-04-24 Dana-Farber Cancer Institute, Inc. Petites molécules marquées de façon hydrophobe en tant qu'inducteurs de la dégradation de protéine
MX363243B (es) 2012-11-28 2019-03-14 Merck Sharp & Dohme Composiciones para tratar cáncer y usos de dichas composiciones.
RU2690663C2 (ru) 2012-12-20 2019-06-05 Мерк Шарп И Доум Корп. Замещенные имидазопиридины в качестве ингибиторов hdm2
US9540377B2 (en) 2013-01-30 2017-01-10 Merck Sharp & Dohme Corp. 2,6,7,8 substituted purines as HDM2 inhibitors
US20160194368A1 (en) 2013-09-03 2016-07-07 Moderna Therapeutics, Inc. Circular polynucleotides
ES2676734T3 (es) 2013-10-18 2018-07-24 Syros Pharmaceuticals, Inc. Compuestos heteroatómicos útiles para el tratamiento de enfermedades proliferativas
JP6491202B2 (ja) 2013-10-18 2019-03-27 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド サイクリン依存性キナーゼ７（ｃｄｋ７）の多環阻害剤
US9862688B2 (en) 2014-04-23 2018-01-09 Dana-Farber Cancer Institute, Inc. Hydrophobically tagged janus kinase inhibitors and uses thereof
US10017477B2 (en) 2014-04-23 2018-07-10 Dana-Farber Cancer Institute, Inc. Janus kinase inhibitors and uses thereof
JO3589B1 (ar) 2014-08-06 2020-07-05 Novartis Ag مثبطات كيناز البروتين c وطرق استخداماتها
WO2016105528A2 (fr) 2014-12-23 2016-06-30 Dana-Farber Cancer Institute, Inc. Inhibiteurs de la kinase cycline-dépendante 7 (cdk7)
CA2978518C (fr) 2015-03-27 2023-11-21 Nathanael S. Gray Inhibiteurs de kinases cycline-dependantes
EP3307728A4 (fr) 2015-06-12 2019-07-17 Dana Farber Cancer Institute, Inc. Thérapie d'association utilisant des inhibiteurs de transcription et des inhibiteurs de kinases
EP4019515A1 (fr) 2015-09-09 2022-06-29 Dana-Farber Cancer Institute, Inc. Inhibiteurs de kinases cycline-dépendantes
JOP20190055A1 (ar) 2016-09-26 2019-03-24 Merck Sharp & Dohme أجسام مضادة ضد cd27
AU2018252546A1 (en) 2017-04-13 2019-10-10 Sairopa B.V. Anti-SIRPα antibodies
US10947234B2 (en) 2017-11-08 2021-03-16 Merck Sharp & Dohme Corp. PRMT5 inhibitors
WO2019148412A1 (fr) 2018-02-01 2019-08-08 Merck Sharp & Dohme Corp. Anticorps bispécifiques anti-pd-1/lag3
EP3833668A4 (fr) 2018-08-07 2022-05-11 Merck Sharp & Dohme Corp. Inhibiteurs de prmt5
WO2020033284A1 (fr) 2018-08-07 2020-02-13 Merck Sharp & Dohme Corp. Inhibiteurs de prmt5

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6322081A (ja) * 1986-07-11 1988-01-29 Kissei Pharmaceut Co Ltd 新規なアミノ酸誘導体
FI89058C (fi) * 1987-02-27 1993-08-10 Yamanouchi Pharma Co Ltd Foerfarande foer framstaellning av som remin-inhibitorer anvaenda 2-(l-alanyl-l-histidylamino)-butanol-derivat
US5223489A (en) * 1987-06-22 1993-06-29 Ujisawa Pharmaceutical Co., Ltd. Amino acid derivatives, processes for the preparation thereof and pharmaceutical composition comprising the same
GB2210875B (en) * 1987-10-09 1991-05-29 Farmos Oy Aromatase inhibiting 4(5)-imidazoles
US5541213A (en) * 1993-06-24 1996-07-30 Eisai Co., Ltd. Propenoic acid derivatives diazole propenoic acid compounds which have useful pharmaceutical utility
US5571792A (en) * 1994-06-30 1996-11-05 Warner-Lambert Company Histidine and homohistidine derivatives as inhibitors of protein farnesyltransferase

Also Published As

Publication number Publication date
US6008372A (en) 1999-12-28
WO1997026246A1 (fr) 1997-07-24
AU1529997A (en) 1997-08-11

Similar Documents

Publication Publication Date Title
ZA97327B (en) Substituted histidine inhibitors of protein farnesyltransferase
AU2805897A (en) Inhibitors of protein farnesyltransferase
PL328868A1 (en) Inhibitors of pharnesil protein transferase
AP9701054A0 (en) Inhibitors of cycteine protease
PL322549A1 (en) Inhibitors of proteinous farnesiltransferase
PL340727A1 (en) Benzothiazolic inhibitors of proteinous thyrosinic kinase
PH11998001073B1 (en) Inhibitors of protein isoprenyl transferases
PL334846A1 (en) Sulphamidic inhibitors of metaloproteases
IL118101A0 (en) Inhibitors of farnesyltransferase
PL322584A1 (en) Inhibitors of proteinous kinase c
PL326754A1 (en) Inhibitors of proteinous kinase c
PL331254A1 (en) Phosphonianic inhibitors of matrix metaloproteases
PL331856A1 (en) Heterocyclic inhibitors of metaloprotease
EP0918771A4 (fr) Thiadioxobenzodiazepines utilises comme inhibiteurs de la farnesyle proteine transferase
PL327569A1 (en) Promedications of thrombosin inhibitors
HUP9904239A3 (en) High level expression of proteins
EP0994856A4 (fr) Inhibiteurs de farnesyl proteine transferase
AU1271297A (en) Inhibitor of ceramidase
PT927183E (pt) Inibidores espirociclicos de metaloproteases
GB2309326B (en) An objectbase of persistent application objects
PL340838A1 (en) Application of the renin-angiotensin system inhibitors
PL328665A1 (en) Inhibitors of serinic protease
EP1027042A4 (fr) Inhibiteurs de la transferase farnesyle proteine
PL334975A1 (en) Application of gasto-intestinal lipase inhibitors
PL337725A1 (en) Inhibitors of proteases